HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hungary Reverse-Switches High-Dose Ibuprofen

Executive Summary

OTC ibuprofen products marketed by Sanofi, Mylan and Zambon among those reverse-switched to Rx status by Hungary's drug regulator.

You may also be interested in...



Next Generation OTC Painkillers And Cough Syrup On Cards For German Switch Committee

Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.

EMA Quashes Claims That Ibuprofen Worsens Infection From Coronavirus

Breaking News: The European Medicines Agency says there is no evidence that ibuprofen worsens Covid‑19 and that consumers can carry on using the drug as advised by patient information. 

Serious Skin Reactions Reported With Ibuprofen Use In Europe

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) advises ibuprofen manufacturers to add warnings of acute generalised exanthematous pustulosis associated with use of the drug to patient information leaflets.

Topics

UsernamePublicRestriction

Register

RS150005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel